Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
The system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, modulates the role of hormones in the genesis and progression of breast tumors. We investigated whether the expression of RANK was related with clinicopathological features of primary endometrial...
Main Authors: | Raúl Gómez, Ana Castro, Jessica Martínez, Víctor Rodríguez-García, Octavio Burgués, Juan J. Tarín, Antonio Cano |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/19/7/1848 |
Similar Items
-
Immunohistochemical expression of hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP -2 and -9 in endometrial polyps and endometrial cancer type I
by: Peres GF, et al.
Published: (2018-07-01) -
Mesonephric-like Differentiation of Endometrial Endometrioid Carcinoma: Clinicopathological and Molecular Characteristics Distinct from Those of Uterine Mesonephric-like Adenocarcinoma
by: Sujin Park, et al.
Published: (2021-08-01) -
Endometrial thickness cut-off value by transvaginal ultrasonography for screening of endometrial pathology in premenopausal and postmenopausal women
by: Yu Ran Park, et al.
Published: (2019-11-01) -
Impact of serum adipokines on tumor mitotic and apoptotic activity in endometrial cancer
by: Mehmet Kefeli, et al.
Published: (2019-07-01) -
Prognostic and Clinicopathological Significance of Hypoxia-Inducible Factor-1α in Endometrial Cancer: A Meta-Analysis
by: Ping Zhu, et al.
Published: (2020-11-01)